Mark Hensley serves as Executive Vice President and Chief Operating Officer at Heron Therapeutics Inc., a commercial-stage biotechnology company dedicated to improving the lives of patients with cancer through innovative therapies. In this pivotal role, he oversees all operational aspects of the business, including manufacturing, supply chain management, quality assurance, commercial operations, and facilities. Hensley's leadership ensures the seamless production and distribution of key products like SUSTOL® (granisetron extended-release injection) for chemotherapy-induced nausea and vomiting, and ZYNRELEF® (bupivacaine and meloxicam extended-release solution), the first and only extended-release, non-opioid analgesic for post-surgical pain. With over 25 years of experience in the pharmaceutical and biotechnology industries, Hensley brings a wealth of expertise in operational excellence and product commercialization. Prior to joining Heron in 2018, he was Chief Operating Officer at BioDelivery Sciences International (BDSI), where he directed the scale-up of manufacturing and successful launches of multiple FDA-approved products utilizing novel drug delivery technologies. Before BDSI, he served as Vice President of Operations at DAVA Pharmaceuticals, leading the commercial launch of Zofran ODT, and held progressive leadership roles at Pfizer spanning more than a decade, focusing on global manufacturing, process optimization, and supply chain strategies. Under Hensley's stewardship, Heron has achieved significant operational milestones, including expanding manufacturing capacity to meet surging demand for ZYNRELEF and enhancing supply chain resilience amid industry challenges. His strategic vision has optimized costs, improved product quality, and supported revenue growth, positioning Heron for sustained success in the oncology supportive care market. Hensley's proven track record continues to drive the company's commitment to delivering high-quality, patient-centric therapies.